Aker BioMarine Takes Innovative Steps to Address the Aging Population Challenge
The Chinese market is important to Aker BioMarine, and as for other developed countries, China is facing the challenge of an ageing population.
Based on calculations, China’s elderly dependency ratio is projected to be 21% in 2035, classifying it as a deep aging society and eventually a super aging society. Although China became an aging society later than other developed countries, the transition time for different aging population cohorts has been shorter. This indicates that China is facing a challenging situation compared to other countries.
According to current projections, China’s rapidly aging population is expected to be associated with a 40% increase in the burden of chronic noncommunicable diseases, such as cardiovascular disease, by 2030. By that time, the number of individuals living with at least one chronic disease is expected to triple for both men and women.
The estimated healthcare costs spent on the elderly, including care and medical services, are projected to reach 26.24% of China’s GDP by 2050, a significant increase from 7.33% in 2015.
Nutrition and supplements can play a significant role in mitigating the healthcare costs related to a global aging population. A study conducted by Food Supplements Europe in 2016 demonstrated that every Euro a consumer spends on omega-3 products can generate 2.3 euros in savings in the healthcare system.
Can we slow down aging? https://www.aftenposten.no/kultur/i/dw0eGJ/hevder-en-pille-kan-reversere-aldring
Omega-3s are essential for human health and well-being, yet an estimated 97 percent of the population has suboptimal omega-3 levels, leaving them vulnerable to increased risks of lifestyle diseases. Krill oil has the potential to reduce the risk of various lifestyle diseases, such as heart and brain-related issues, while potentially improving overall life quality and saving billions of dollars for society.
By delivering 5 billion doses of health-promoting nutrients by 2030, Aker BioMarine aims to contribute to the improvement of general health and support efforts in alleviating lifestyle diseases.
Scientific research is an essential part of our business model. In fact, since 2006, Aker BioMarine has made significant investments in science, research, and development, as well as intellectual property, with the aim of understanding the nutritional value and potential health benefits of krill oil. Our focus in scientific research encompasses a wide range of areas, from investigating how krill oil phospholipids support general health and wellness to exploring its effects on specific health conditions such as heart and liver health, cognitive health, joint and muscle health, sports performance, skin health, eye health, and even addressing symptoms of PMS (premenstrual syndrome).
Read more here: https://www.akerbiomarine.com/news/2022-krill-science-highlights
Throughout our research endeavors, we have placed particular emphasis on measuring the omega-3 index, which serves as a valid biomarker for assessing the incorporation of omega-3 fatty acids into cellular and tissue structures. This allows us to gain insights into the efficacy and benefits of krill oil.
Aker BioMarine’s commitment to scientific excellence is evident through our contributions to over 200 articles and more than 50 studies focused on the health benefits of krill oil. These publications have appeared in prestigious, top-tier scientific journals, emphasising the credibility, relevance, and strength of our study outcomes. Our research adheres to gold standard clinical practices, employing methodologies such as randomised, double-blind, placebo-controlled trials, and all studies undergo thorough peer review.
By conducting rigorous and comprehensive research, we strive to deepen our understanding of krill oil’s potential health benefits and ensure that our products are supported by scientific evidence of the highest caliber.
About Aker BioMarine
Aker BioMarine is a biotech innovator and Antarctic krill-harvesting company, dedicated to improving human and planetary health. Listed on the Oslo Stock Exchange, we develop krill-based ingredients for nutraceutical (Superba®) animal feed (QRILL® Pet), and aquaculture( QRILL® Aqua), applications. We also develop INVI™, a highly concentrated protein isolate, and LYSOVETA™, a product area targeting brain health. As a global leader in marine phospholipids, Aker BioMarine’s fully transparent value chain starts with sustainable krill harvesting in pristine Antarctic waters before traveling through the company’s Montevideo based logistics hub and Houston based production plant, before product is shipped to customers around the world. The company’s strong focus on sustainability inspired the launch of AION by Aker BioMarine, a circularity company dedicated to helping companies to recycle and reuse waste.
For other interesting articles from our members and chamber activities, please visit our website.